KINDSTAR GLOBAL (09960): Wuhan Kangshengda plans to acquire 40% equity of Huaxi Kangshengda for RMB 12.396 million.

KINDSTAR GLOBAL (09960) Announcement: Wuhan Kangshengda (a comprehensive entity in China) successfully acquired 40% equity of Huaxi Kangshengda (a comprehensive entity in China) through the open bidding process of Beijiao Exchange on November 25, 2025. Wuhan Kangshengda and Huaxi Health Technology entered into a property transaction agreement, with Wuhan Kangshengda agreeing to acquire and Huaxi Health Technology agreeing to sell 40% equity of Huaxi Kangshengda for a total sum of RMB 1239.6 million. After the completion of this transaction, Huaxi Kangshengda will become an indirect wholly-owned subsidiary of the Company. After thorough evaluation by the board of directors, it is believed that this transaction is in the overall interest of the Company and its shareholders, specifically: (1) Huaxi Kangshengda, as the core platform of the Group's "National Special Inspection Network + Regional Center Laboratory" strategy in the Southwest region, has become a regional high-end special inspection service provider covering Sichuan, Chongqing, Yunnan, and Guizhou, with scale testing capabilities and mature experience in areas such as tumor early screening and molecular diagnostics. Achieving full ownership will help strengthen the Group's overall strategic management of Huaxi Kangshengda's business operations and direction, ensuring the efficient and consistent execution of the Group's overall strategy in the Southwest region; (2) As a leading third-party medical testing (ICL) platform, Huaxi Kangshengda will strongly support the Group's dual-track development strategy of "ICL + IVD," effectively promoting the synergistic effect of "driving IVD product development with ICL, and upgrading ICL services with IVD"; (3) The Company will fully lead the appointment of Huaxi Kangshengda's management team, performance assessment, and resource allocation, further enhancing the efficiency of cross-regional projects (such as the joint construction of regional testing centers, cooperation with grassroots medical institutions, etc.). The Company will also continue and deepen its clinical and research cooperation with West China Hospital of Sichuan University, better integrating the channels, technologies, and medical resources in the Southwest region, strengthening regional operational capabilities.